Skip to main content
. 2020 Jun 10;155(7):572–579. doi: 10.1001/jamasurg.2020.1133

Figure 3. Expression Levels and Diagnostic Values of Gastric Cancer (GC)–Associated Long Noncoding RNA1 (lncRNA-GC1), Carcinoembryonic Antigen (CEA), Cancer Antigen 72-4 (CA72-4), and CA19-9 in the Verification Phase.

Figure 3.

A, The relative levels of circulating exosomal lncRNA-GC1 in patients with GC (n = 386), patients with chronic atrophic gastritis (CAG) (n = 37), patients with intestinal metaplasia (IM) (n = 48), healthy donor individuals with positive Helicobacter pylori (HD+) (n = 64), and healthy donor individuals (HDs) with negative H pylori (HD-) (n = 87). B, The receiver operating characteristic curves of lncRNA-GC1, CEA, CA72-4, and CA19-9 in distinguishing GC from HD. C, The relative levels of circulating exosomal lncRNA-GC1 in stage I GC (n = 85), stage II GC (n = 94), CAG (n = 37), IM (n = 48), and HD (n = 151). D, The receiver operating characteristic curves of lncRNA-GC1, CEA, CA72-4, and CA19-9 used to distinguish patients with early GC (EGC) from HDs. Early GC was defined as stages I and II GC. The results are presented as mean (SD). NS indicates not significant.

aP < .001.

bP < .01.